公开(公告)号：US20160347850A1

公开(公告)日：2016-12-01

申请号：US15167598

申请日：2016-05-27

Applicant: AbbVie Inc.

Inventor： Lorenzo Benatuil ,  Bradford L. McRae ,  Maria A. Argiriadi ,  Chung-Ming Hsieh

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  G01N33/566

CPC classification number: C07K16/2878 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/566 ,  G01N2333/70578

Abstract: The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.

Abstract translation: 本发明包括拮抗性抗CD40抗体及其抗原结合部分。 具体地，本发明涉及人源化抗-CD40抗体。 在某些实施方案中，本发明的抗体中和人CD40（hCD40）活性。 本发明的抗体或抗体部分可用于检测CD40和抑制CD40活性，例如在患有CD40活性有害的病症的人类受试者中。

公开(公告)号：US20160200813A1

公开(公告)日：2016-07-14

申请号：US14967260

申请日：2015-12-11

Applicant: AbbVie Inc.

Inventor： Lorenzo Benatuil ,  Kangwen Deng ,  Denise Karaoglu Hanzatian ,  Maria A. Argiriadi

IPC: C07K16/28 ,  G01N33/566 ,  A61K39/395 ,  A61K47/48 ,  A61K45/06

CPC classification number: C07K16/28 ,  A61K38/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6849 ,  A61K2039/505 ,  C07K14/705 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/53 ,  G01N33/566 ,  G01N2333/705

Abstract: The disclosure provides binding proteins that specifically bind to LRP-8 and optionally cross the blood brain barrier (BBB), localize to the brain and/or localize to the spinal cord.

Abstract translation: 本公开提供了特异性结合LRP-8并且任选地穿过血脑屏障（BBB）的结合蛋白，定位于大脑和/或定位于脊髓。

公开(公告)号：US20160153001A1

公开(公告)日：2016-06-02

申请号：US14925939

申请日：2015-10-28

Applicant: AbbVie Inc.

Inventor： Chung-ming Hsieh ,  Jonathan P. Belk ,  Jennifer M. Perez ,  Lorenzo Benatuil

IPC: C12N15/87

CPC classification number: C12N15/87 ,  C12N1/16 ,  C12N1/18 ,  C12N13/00

Abstract: This invention is directed to the transformation of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.

Abstract translation: 本发明涉及通过电穿孔转化酵母及其突变体，其导致表达重组产物的稳定转化的酵母宿主细胞。 本发明还涉及转化的酵母细胞和文库。

公开(公告)号：US20160060332A1

公开(公告)日：2016-03-03

申请号：US14822329

申请日：2015-08-10

Applicant: Abbvie Inc.

Inventor： Lorenzo Benatuil ,  Erwin R. Boghaert ,  Jijie Gu ,  Maria Harris ,  Jonathan A. Hickson ,  Chung-Ming Hsieh ,  Yuliya Kutskova ,  Yingchun Li ,  Zhihong Liu ,  Susan Morgan-Lappe

IPC: C07K16/22

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。